Q-omics provides the consensus-scored CCDC173 profile across patient tissues and cancer cell-line models. CCDC173 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, CCDC173 is differentially expressed in 7, with the highest sampling consensus in LUAD. Additionally, CCDC173 RNA expression shows 18,834 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight BRCA, LUAD, and KIRP as cancer lineages where CCDC173 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC173 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC173 survival associations across molecular data types. CCDC173 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC173 RNA expression–survival associations across cancer types. High CCDC173 expression shows unfavorable associations in LIHC and KICH, but favorable associations in BRCA, HNSC, PAAD and UVM. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for CCDC173 RNA expression.
This table summarizes CCDC173 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CCDC173. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC173 shows lower tumor expression in LUAD, KICH, THCA, LUSC, BLCA and BRCA. The LUAD box plot shows higher CCDC173 RNA expression in normal versus tumor tissue (log2 FC = −1.593, t-test p < 0.001).
This table shows molecular features associated with CCDC173 in patient tissues and cancer cell lines. In patient samples, CCDC173 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC173 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
